New hope for myeloma: targeted drug combo takes on Tough-to-Treat cancer

NCT ID NCT06868667

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new combination of drugs—belantamab mafodotin plus bortezomib and dexamethasone—works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people in Japan with multiple myeloma that has come back or stopped responding to treatment. About 24 participants will be randomly assigned to one of the two combos. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin (a targeted antibody-drug conjugate) combined with bortezomib and dexamethasone
What this could lead to: If this works, it could offer a new treatment option for people with multiple myeloma that has come back or stopped responding to earlier therapy.
What could go wrong: This is a small, early-phase study in Japan only, so results may not apply broadly. The experimental combo may not prove better than the standard daratumumab combo, and side effects like eye problems are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

GSK Investigational Site

Aomori, Japan
GSK Investigational Site

Fukuoka, Japan
GSK Investigational Site

Himeji, Japan
GSK Investigational Site

Kamakura, Japan
GSK Investigational Site

Kitakyushu, Japan
GSK Investigational Site

Kochi, Japan
GSK Investigational Site

Matsuyama, Japan
GSK Investigational Site

Nagoya, Japan
GSK Investigational Site

Okayama, Japan
GSK Investigational Site

Osaka, Japan
GSK Investigational Site

Ōgaki, Japan
GSK Investigational Site

Shibukawa, Japan
GSK Investigational Site

Sunto-gun, Japan
GSK Investigational Site

Suwa, Japan
GSK Investigational Site

Toyohashi, Japan
GSK Investigational Site

Yokohama, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.